All Articles
How Big can Merck's Keytruda be in Lung Cancer? It's Too Early to Call in the PD-L1 Arms Race!

How Big can Merck's Keytruda be in Lung Cancer? It's Too Early to Call in the PD-L1 Arms Race!

19 May, 2015

Maria Fe Paz and Peter Keeling of Diaceutics discuss the competitiveness of the PD-L1 market and highlight that the key to success, for those in pharma, will be ensuring they leverage all the test adoption drivers to support uptake of the therapy.|Maria Fe Paz and Peter Keeling of Diaceutics discuss the competitiveness of the PD-L1 market and highlight that the key to success, for those in pharma, will be ensuring they leverage all the test adoption drivers to support uptake of the therapy.|Maria Fe Paz and Peter Keeling of Diaceutics discuss the competitiveness of the PD-L1 market and highlight that the key to success, for those in pharma, will be ensuring they leverage all the test adoption drivers to support uptake of the therapy.|Maria Fe Paz and Peter Keeling of Diaceutics discuss the competitiveness of the PD-L1 market and highlight that the key to success, for those in pharma, will be ensuring they leverage all the test adoption drivers to support uptake of the therapy.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.